Post-Authorization Safety Study for Assessment of Pregnancy and Infant Outcomes in Patients Treated With Kesimpta (Ofatumumab) Using OTIS Observational Pregnancy Surveillance Program and DMSKW Registry
Latest Information Update: 17 Jan 2025
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 16 Jan 2023 Status changed from not yet recruiting to recruiting.
- 06 Dec 2022 New trial record